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Peripheral Direct Adjacent Lobe Invasion Non-small Cell
Lung Cancer Has a Similar Survival to That of Parietal
Pleural Invasion T3 Disease
Hao-Xian Yang, MD, PhD,*† Xue Hou, MD,‡ Peng Lin, MD, PhD,*† Hong Yang, MD,*†
Can-Guang Zeng, MD,*† Tie-Hua Rong, MD,*† and Jian-Hua Fu, MD, PhD*†
Introduction: The postoperative prognosis of peripheral adjacent
lobe invasion non-small cell lung cancer (NSCLC) is unclear. The
purpose of this study was to determine the postoperative prognosis
of NSCLC with direct adjacent lobe invasion by comparing it with
that of visceral pleural invasion (primary lobe) T2 disease, and
parietal pleural invasion T3 disease, and hence determine its most
appropriate T category.
Methods: A retrospective analysis was conducted to assess the
survival of patients with peripheral direct adjacent lobe invasion
NSCLC (group A), and it was compared with that of patients with
visceral pleural invasion of the primary lobe (group B) and parietal
pleural invasion (group C). All patients were node-negative on
pathologic examination. Kaplan-Meier method was used to compare
the postoperative survival between groups.
Results: A total of 263 patients were analyzed. The overall survival
rates in groups A (n  28), B (n  167), and C (n  68) at 5 years
were 40.7, 54.6, and 41.9%, respectively; corresponding median
survival in three groups were 53, 71, and 40 months, respectively.
The survival difference among three groups was statistically signif-
icant (p  0.031). A similar survival was observed between groups
A and C, whereas group B had a much better survival than other
groups.
Conclusions: Peripheral adjacent lobe invasion NSCLC has a sim-
ilar survival prognosis with that of parietal pleural invasion T3
disease and hence should be classified as T3 rather than T2.
However, further studies are warranted.
Key Words: Lung cancer surgery, Lung cancer, Diagnosis and
staging.
(J Thorac Oncol. 2009;4: 1342–1346)
The tumor, node, metastasis (TNM) staging system of lungcancer is used as a guide for the prognosis of patients with
non-small cell lung cancer (NSCLC).1 According to the 6th
and proposed 7th revision of International Association for the
Study of Lung Cancer (IASLC) staging system, direct inva-
sion of peripheral adjacent lobe is defined as T2 disease.
However, the postoperative prognosis of these patients is
controversial.2,3 The purpose of this study was to determine
the postoperative prognosis of NSCLC with direct adjacent
lobe invasion by comparing it with that of visceral pleural
invasion (same lobe) T2 disease and parietal pleural invasion
T3 disease, and hence determine its most appropriate T
category.
MATERIALS AND METHODS
Patients Selection
We conducted the study using data extracted from a
prospectively collected NSCLC database, which is composed
of 2094 surgically managed cases at thoracic surgery depart-
ment, Sun Yat-sen University Cancer Center from March
1997 to October 2006. The patients receiving complete or
incomplete lung resections were included in the database. We
applied the definition of complete surgical resection proposed
by the IASLC Staging Committee.4 The direct adjacent lobe
invasion was defined by contiguous extension of the primary
tumor across a fissure into another lobe.
Preoperative workup for patients included chest com-
puted tomography (CT), brain magnetic resonance, B ultra-
sound or CT scan for abdomen, and a bone scan. Mediastinal
lymph node involvement (short diameter 1 cm) was ex-
cluded preoperatively by CT scan. Mediastinoscopy was not
routinely performed as part of preoperative workup. In all
patients, routine biochemical profile, fibrobronchoscopy, pul-
monary function tests with spirometry, and arterial blood gas
analysis at rest were also required.
The patients involved in our analysis fit the criteria as
follows: (1) pathologically confirmed diagnosis of primary
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NSCLC; (2) peripheral NSCLC with direct pathologic adja-
cent lobe invasion (classified in group A), NSCLC with
visceral pleural invasion of the same lobe by the primary
tumor (pathologic T2 disease, classified in group B), or
NSCLC with pathologic parietal pleural invasion T3 disease
(classified in group C); (3) the tumor were considered resect-
able preoperatively and received surgical management; and
(4) pathologically confirmed N0M0 disease after surgery. We
defined peripheral tumors as those where the center of mass
was beyond the debouchement of the segmental bronchus,
and central tumors as those where the center of mass was at
the proximal side of the debouchement of the segmental
bronchus. We applied the proposed 7th revision of the IASLC
staging system for patient selection.3,5 Because our main
concern was comparing the prognosis of adjacent lobe inva-
sion with visceral pleural invasion of the same lobe, and with
parietal pleural invasion disease, we did not involve other T2
and T3 descriptors in our analysis.
We excluded the patients with bronchioloalveolar car-
cinoma, small cell lung cancer, M1 disease, superior sulcus
tumor, and patients with a history of concurrent malignant
disease or other previous primary cancers. Cases of synchro-
nous multiple primary lung cancer were excluded according
to the criteria proposed by Martini and Melamed.6 We ex-
cluded the central NSCLC with adjacent lobe invasion to
avoid the confusion in data analysis. The tumors with adja-
cent lobe invasion simultaneously combined with parietal
pleural invasion were also excluded. Because the purpose of
this study was to assess the reasonable T stage for adjacent
lobe invasion NSCLC, we excluded lymph node positive
patients in this analysis.
Follow-Up of Patients
Operative death was defined as death within 1 month
after surgery. A follow-up examination was, in general, done
every 2 months for the first year, 3 months for the second
year, and 4 months thereafter. The examination included a
physical examination, blood chemistry, and chest radiogra-
phy. In addition, all patients routinely received chest scan by
CT, head scan by magnetic resonance or CT, and radionu-
clide bone scan. However, if the patient had specific symp-
toms, the examination was performed as soon as possible for
a more careful assessment. The median time from surgery to
the last contact for the entire cohort was 65.7 months, ranging
from 0.7 to 101 months.
Statistical Methods
SPSS 16.0 software was used for statistical analysis.
Survival was calculated by Kaplan-Meier method, and log-
rank test was used to assess differences in survival between
groups. A two-sided p value of less than 0.05 was considered
statistically significant. Patients alive at the end of the study
period were censored for the purpose of data analysis.
RESULTS
Patients Demographics and Treatment
Information
There were 263 patients derived from the previously
collected database according to the inclusion criteria. The
patient numbers involved in groups A, B, and C were 28, 167,
and 68, respectively. Twenty-one adjacent lobe invasion
cases in group A were identified on CT scan before surgery,
and the others were detected by examination during surgery.
Table 1 gives the details of the patients.
The posterolateral thoracotomy was routinely used, and
the type of lung resection is shown in Table 1. Systematic
mediastinal lymph nodes dissection or sampling was per-
formed during surgery. For patients received exploratory
thoracotomy without lung resection, mediastinal sampling
was performed to achieve an accurate pathologic stage. All
patients in group A received complete resection with a
negative resection margin (R0); whereas in other groups,
some patients were with microscopically positive residue
TABLE 1. Demographic Features and Treatment
Information About the Patients
Characteristics
Group A
(n  28)
Group B
(n  167)
Group C
(n  68) p
Gender
Male 17 98 42 0.427a
Female 11 69 26
Median age/yr (range) 64 (40–77) 63 (32–82) 59 (35–78) —
Tumor size (mean
cm  SD)
5.4  1.6 4.6  1.4 5.3  1.6 0.683b
FEV1 before surgery
(mean liter  SD)
1.74  0.13 1.82  0.10 1.76  0.12 0.752b
Pathology
Squamous cell
carcinoma
18 60 23 0.023c
Adenocarcinoma 7 84 33
ASC 3 6 4
Others 0 17d 8e
Type of surgery
Bilobectomy 3f 20 3 —
Lobectomy  wedge 7g 0 0
Single lobe
lobectomy
0 144 63
Right
pneumonectomy
11 1 0
Left pneumonectomy 7 2 2
Resection completeness
R0 28 165 61 —
R1 0 2 4
R2 0 0 3
Postoperative
chemotherapy
Yes 20 122 52 0.638a
No 8 45 17
a Pearson 2 test.
b Independent samples t test.
c Fisher exact test.
d Large cell carcinoma.
e Including six cases of large cell carcinoma, two cases of carcinosarcoma.
f Two cases of primary right upper lobe tumors with middle lobes invasion; one
case of primary middle lobe tumor with lower lobe invasion.
g Two cases of primary right lower lobe tumors with right upper lobes invasion;
four cases of primary left lower lobe tumors with left upper lobes invasion; one case of
primary left upper lobe tumor with left lower lobes invasion.
FEV1, forced expiratory volume in 1 sec; ASC, adenosquamous carcinoma.
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(R1) or gross positive residual (R2) (Table 1). The patients
with incomplete resection received postoperative radiother-
apy followed by platinum-based chemotherapy. The consti-
tute ratio of adenocarcinoma in groups B and C was higher
than that in group A (Table 1). The gender, age, pulmonary
function before surgery (forced expiratory volume in 1 sec-
ond), and administration of postoperative chemotherapy were
well balanced between all groups (Table 1).
In group A, seven patients underwent left pneumonec-
tomy and 11 patients underwent right pneumonectomy because
of the large tumors both in primary and in invaded lobes.
Most patients received two to four cycles of platinum-
based postoperative chemotherapy with variable compliance
within the whole group (Table 1).
Survival
Survival data was collected on each patient from the
date of surgery. There were 11 deaths in group A at the end
of follow-up, including one operative death patient who lived
29 days after surgery. The perioperative death was in a
66-year-old man who underwent right pneumonectomy and
died of pneumonitis caused by bronchopleural fistula. The
other deaths in group A were caused by brain metastases (five
cases), local recurrence (three cases), and multiple organ
metastases (two cases). The overall survival rates including
the operative deaths in group A at 2, 3, and 5 years were 68.7,
61.1, and 40.7%, respectively, with a median survival of 53
months (Figure 1). The operative mortality in groups B and C
was 0.6% (1 of 167) and 1.5% (1 of 68), respectively. The
FIGURE 1. Survival curves of patients for all groups. The survival difference among three groups was statistically significant
(p  0.031). Between groups A and B, p  0.032; between groups A and C, p  0.501; and between groups B and C, p 
0.039.
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overall survival rates for group B and group C at 2, 3, and 5
years were 91.9, 74.3, 54.6%, and 85.6, 61.2, 41.9, respec-
tively; corresponding median survival in two groups were 71
and 40 months, respectively (Figure 1). Among the three
groups, the survival difference was statistically significant (be-
tween groups A and B, p  0.032; between groups A and C,
p  0.501; and between groups B and C, p  0.039; Figure 1).
A similar survival was observed between groups A and C,
whereas group B had a much better survival than other groups.
In group A, the median survival time was 33 months for
patients who had less than pneumonectomy (lobectomy plus
wedge resection), and 53 months for patients who had pneu-
monectomy, but the difference was not statistically signifi-
cant (p  0.244).
DISCUSSION
The TNM staging system for lung cancer is used to help
select the most appropriate treatment for patients on the basis
of the prognosis of different stages of NSCLC.
Direct invasion of peripheral adjacent lobe is currently
T2 (pleural visceral invasion) under the 6th and proposed 7th
revision of IASLC staging system.2,3,5 However, the progno-
sis for NSCLC with adjacent lobe invasion through the fissure
have seldom been reported, and the results are controver-
sial.7,8 In this analysis, our data suggested that the postoper-
ative survival for patients with adjacent lobe invasion was
comparable with that of parietal pleural invasion T3 patients
and lower than other type of T2 (pleural visceral invasion of
the same lobe) patients. Because the TNM staging system for
NSCLC is based on the different prognosis of patients,
comparable prognosis is related to similar stage. In our study,
lung cancer with adjacent lobe invasion had a similar survival
prognosis compared with that of parietal pleural invasion T3
disease. This finding provides possible evidence that the
patients in group A may be classified as T3. Demir et al.7
assessed 60 patients had T2 NSCLC that showed a limited
growth through the interlobar fissure into the adjacent lobe.
The prognosis of their patients was found to be similar with
that of T3 tumors,7 which was comparable with that of our
series. However, different result had also been reported by
other institution. Nonaka et al.8 assessed the survival of 50
NSCLC with interlobar pleural invasion. The 5-year survival
rate of 28 patients with squamous cell carcinoma with inter-
lobar pleural invasion was 69%, similar to 54% with T2 and
hence concluded that tumors with interlobar pleural invasion
should be classified as T2 in squamous cell carcinoma.8 The
discrepancies may be due to the small number, or different
inclusion criteria among studies, suggesting further study
with much larger number is essential to make it clear.
As far as the operation was concerned, the survival
curve of group A seemed to show a better survival prognosis
for patient who underwent pneumonectomy than that of those
receiving less than pneumonectomy (lobectomy plus wedge
resection), although the survival difference was not statisti-
cally significant. The previous data from neoadjuvant chemo-
radiotherapy had shown that the extent of surgery determined
the postoperative mortality and that patients receiving lobec-
tomy had a better survival than that of receiving pneumonec-
tomy.9,10 The patients receiving pneumonectomy were usu-
ally with more advanced disease than those receiving
lobectomy or bilobectomy (right lung), and meant much loss
of pulmonary reserve, so our result in group A seems hard to
explain. This result was interesting, but may not be surpris-
ing, because it may suggest that direct adjacent lobe invasion
should be treated as two primary tumors in different lobes,
and pneumonectomy or at least bilobectomy (right lung) is
more reasonable than lobectomy plus wedge for a complete
resection. Nevertheless, the case of operative death in group
A received right pneumonectomy, and this indicates a more
careful selection before surgery and more intensive care after
surgery should be given to patients receiving pneumonec-
tomy. In our study, the sample size was small, this fact must
be considered when interpreting our data.
Nodal status is generally considered to be an important
prognostic factor in NSCLC.1,11–15 In this retrospective study,
we excluded lymph node positive patients because the pur-
pose of this study was to assess the reasonable T stage for
adjacent lobe invasion NSCLC. Mediastinoscopy is not a
routine procedure in our institute, unless there is suspected
contralateral hilar or mediastinal lymph node involvement.
However, a systematic review of the medical literature relat-
ing to the accuracy of noninvasive staging of the mediastinum
involving 5111 patients with lung cancer showed that the
pooled sensitivities and specificities for staging the medias-
tinum for CT scanning, positron emission tomography scan-
ning, and endoscopic ultrasound were 0.57 and 0.82, 0.84 and
0.89, 0.78 and 0.71, respectively.16 This suggests that nonin-
vasive methods for evaluation of the mediastinal lymph node
are not accurate enough for NSCLC staging before treatment.
Nevertheless, a systematic review of cervical mediastinos-
copy involving 6505 lung cancer cases showed that the
sensitivity and specificity was 78 and 100% respectively.17
Therefore, invasive staging strategy such as mediastinoscopy
examination should be recommended before surgery after-
ward for a careful patient selection in our institute.
In conclusion, our data suggests a similar survival
prognosis of NSCLC with direct adjacent lobe invasion
compared with that of parietal pleural invasion T3 disease.
Therefore, direct adjacent invasion NSCLC should be classi-
fied as T3 rather than T2. However, this result should be
interpreted with caution because of the small size, and further
studies are warranted to assess the rationality of considering
these patients as T3 disease.
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